Hostname: page-component-cd9895bd7-p9bg8 Total loading time: 0 Render date: 2024-12-28T05:17:48.046Z Has data issue: false hasContentIssue false
  • English
  • Français

Risks of neurobehavioral teratogenicity associated with prenatal exposure to valproate monotherapy: a systematic review with regulatory repercussions

Published online by Cambridge University Press:  26 February 2014

Salvatore Gentile
Salvatore Gentile*
Affiliation:
Department of Mental Health, ASL Salerno, Mental Health Centre n. 63, Cava de' Tirreni – Vietri Sul Mare, Salerno, Italy; Medical School “Federico II, ” Department of Neurosciences, University of Naples, Naples, Italy
*
*Address for correspondence: Salvatore Gentile, Department of Mental Health, ASL Salerno, Mental Health Centre n. 63 Cava de' Tirreni - Vietri Sul Mare, Piazza Galdi, 841013 Cava de’ Tirreni, Salerno, Italy. (Email: [email protected])
Get access Rights & Permissions [Opens in a new window]

Abstract

Beyond its formal indications (epilepsy, bipolar disorder, and migraine), valproate sodium (VPA) is widely used in a number of other clinical conditions. Recently, however, the U.S. Food and Drug Administration (FDA) issued a warning regarding a decrease in IQ scores in children prenatally exposed to the drug. For patients with migraine, the pregnancy labeling of VPA will be changed from Category “D” to “X.” VPA products will remain in pregnancy category “D” for treating epilepsy and manic episodes associated with bipolar disorder. Thus, this article aims to assess (through a computerized Medline/PubMed search) the neurobehavioral teratogenicity of valproate monotherapy, in order to evaluate alternative regulatory decisions. Reviewed information suggests a detrimental impact of antenatal valproate exposure on the global child neurodevelopment. Affected areas include not just reduced IQ scores, but also behavioral problems and a potential increase in the risk for a future diagnosis of attention-deficit/hyperactivity disorder. An increased risk of developing autism-spectrum disorders has also been reported. Thus, in my opinion, VPA should be assigned definitively to the Category “X,” independent of any considerations about its clinical indications, and should be strictly avoided during pregnancy, due to the demonstrated risk of both neurobehavioral and neurocognitive teratogenicity.

Keywords

neurobehavioral teratogenicitypregnancyvalproate
Type
Review Articles
Information
CNS Spectrums , Volume 19 , Issue 4 , August 2014 , pp. 305 - 315
Copyright
Copyright © Cambridge University Press 2014 

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

1.Johannessen Landmark, C, Larsson, PG, Rytter, E, Johannessen, SI. Antiepileptic drugs in epilepsy and other disorders--a population-based study of prescriptions. Epilepsy Res. 2009; 87(1): 31–39.CrossRefGoogle Scholar
2.Hayes, J, Prah, P, Nazareth, I, etal. Prescribing trends in bipolar disorder: cohort study in the United Kingdom THIN primary care database 1995–2009. PLoS One. 2011; 6(12): e28725.Google Scholar
3.Barbui, C, Conti, V, Purgato, M, etal. Use of antipsychotic drugs and mood stabilizers in women of childbearing age with schizophrenia and bipolar disorder: epidemiological survey. Epidemiol Psychiatr Sci. 2013; 22(4): 355–361.Google Scholar
4.Adedinsewo, DA, Thurman, DJ, Luo, YH, etal. Valproate prescriptions for nonepilepsy disorders in reproductive-age women. Birth Defects Res A Clin Mol Teratol. 2013; 97(6): 403–408.CrossRefGoogle ScholarPubMed
5.Gentile, S. Prophylactic treatment of bipolar disorder in pregnancy and breastfeeding: focus on emerging mood stabilizers. Bipolar Disord. 2006; 8(3): 207–220.Google Scholar
6.Gentile, S. Bipolar disorder and pregnancy: to treat or not to treat? BMJ. 2012; 345: e7367.Google Scholar
7.Vajda, FJ, O'Brien, TJ, Graham, JE, Lander, CM, Eadie, MJ. Dose dependence of fetal malformations associated with valproate. Neurology. 2013; 81(11): 999–1003.Google Scholar
8.Meador, KJ. Comment: valproate dose effects differ across congenital malformations. Neurology. 2013; 81(11): 1002.CrossRefGoogle ScholarPubMed
9.Pennell, PB, Klein, AM, Browning, N, etal. Differential effects of antiepileptic drugs on neonatal outcomes. Epilepsy Behav. 2012; 24(4): 449–456.Google Scholar
10.FDA Drug Safety Communication. Valproate anti-seizure products contraindicated for migraine prevention in pregnant women due to decreased IQ scores in exposed children. http://www.fda.gov/Drugs/DrugSafety/ucm350684.htm. Accessed: July 5, 2013.Google Scholar
11.Koch, S, Titze, K, Zimmermann, RB, etal. Long-term epilepsy and neuropsychological consequences of maternal anticonvulsant treatment during pregnancy for school-age children and adolescents. Epilepsia. 1999; 40(9): 1237–1243.CrossRefGoogle ScholarPubMed
12.Neurobehavioral Teratology Society. http://www.nbts.org/about-nbts/. Accessed February 15, 2014.Google Scholar
13.Steinhausen, HC, Losche, G, Koch, S, Helge, H. The psychological development of children of epileptic parents. I. Study design and comparative findings. Acta Paediatr. 1994; 83(9): 955–960.Google Scholar
14.Losche, G, Steinhausen, HC, Koch, S, Helge, H. The psychological development of children of epileptic parents. II. The differential impact of intrauterine exposure to anticonvulsant drugs and further influential factors. Acta Paediatr. 1994; 83(9): 961–966.Google Scholar
15.Koch, S, Jäger-Roman, E, Lösche, G, etal. Antiepileptic drug treatment in pregnancy: drug side effects in the neonate and neurological outcome. Acta Paediatr. 1996; 84(6): 739–746.Google Scholar
16.Adab, N, Jacoby, D, Smith, D, Chadwick, D. Additional educational needs in children born to mothers with epilepsy. J Neurol Neurosurg Psychiatry. 2001; 70(1): 15–21.Google Scholar
17.Dean, CS, Hailey, H, Moore, SJ, etal. Long term health and neurodevelopment in children exposed to antiepileptic drugs before birth. J Med Genet. 2002; 39(4): 251–259.CrossRefGoogle ScholarPubMed
18.Gaily, E, Kantola-Sorsa, E, Hiilesmaa, V, etal. Normal intelligence in children with prenatal exposure to carbamazepine. Neurology. 2004; 362(1): 28–32.Google Scholar
19.Eriksson, K, Viinikainen, K, Monkkonen, A, etal. Children exposed to valproate in utero—population based evaluation of risks and confounding factors for long-term neurocognitive development. Epilepsy Res. 2005; 65(3): 189–200.Google Scholar
20.Viinikainen, K, Eriksson, K, Monkkonen, A, etal. The effects of valproate exposure in utero on behavior and the need for educational support in school-aged children. Epilepsy Behav. 2006; 9(4): 636–640.Google Scholar
21.Thomas, SV, Ajaykumar, B, Sindhu, K, etal. Motor and mental development of infants exposed to antiepileptic drugs in utero. Epilepsy Behav. 2008; 13(1): 229–236.Google Scholar
22.Meador, KJ, Baker, GA, Browning, N, etal. for the NEAD Study Group. Cognitive function at 3 years of age after fetal exposure to antiepileptic drugs. N Engl J Med. 2009; 360(16): 1597–1605.CrossRefGoogle Scholar
23.McVearry, KM, Gaillard, WD, VanMeter, J, Meador, KJ. A prospective study of cognitive fluency and originality in children exposed in utero to carbamazepine, lamotrigine, or valproate monotherapy. Epilepsy Behav. 2009; 16(4): 609–616.CrossRefGoogle ScholarPubMed
24.Cohen, MJ, Meador, KJ, Browning, N, etal. Fetal antiepileptic drug exposure: motor, adaptive, and emotional/behavioral/functioning at age 3 years. Epilepsy Behav. 2011; 22(2): 240–246.CrossRefGoogle ScholarPubMed
25.Meador, KJ, Baker, GA, Browning, N, etal. for the NEAD Study Group. Effects of fetal antiepileptic drug exposure: outcomes at age 4.5 years. Neurology. 2012; 78(16): 1207–1214.Google Scholar
26.Meador, KJ, Baker, GA, Browning, N, etal. for the NEAD Study Group. Fetal antiepileptic drug exposure and cognitive outcomes at age 6 years (NEAD study): a prospective observational study. Lancet Neurol. 2013; 12(3): 244–252.Google Scholar
27.Cohen, MJ, Meador, KJ, Browning, N, etal, for the NEAD study group. Fetal antiepileptic drug exposure: adaptive and emotional/behavioral functioning at age 6 years. Epilepsy Behav. 2013; 29(2): 308–315.Google Scholar
28.Meador, KJ, Baker, GA, Browning, N, etal, for the NEAD Study Group. Foetal antiepileptic drug exposure and verbal versus non-verbal abilities at three years of age. Brain. 2011; 134(Pt 2): 396–404.Google Scholar
29.Adab, N, Kini, U, Vinten, J, etal. The longer term outcome of children born to mothers with epilepsy. J Neurol Neurosurg Psychiatry. 2004; 75(11): 1575–1583.Google Scholar
30.Vinten, J, Adab, N, Kini, U, etal, for the Liverpool and Manchester Neurodevelopment Study Group. Neuropsychological effects of exposure to anticonvulsant medication in utero. Neurology. 2005; 64(6): 949–954.Google Scholar
31.Vinten, J, Bromley, RL, Taylor, J, etal, on behalf of the Liverpool and Manchester Neurodevelopment Group. The behavioral consequences of exposure to antiepileptic drugs in utero. Epilepsy Behav. 2009; 14(1): 197–201.Google Scholar
32.Bromley, RL, Mawer, G, Love, J, etal, on behalf of the Liverpool and Manchester Neurodevelopment Group. Early cognitive development in children born to women with epilepsy: a prospective report. Epilepsia. 2010; 51(10): 2058–2065.Google Scholar
33.Shallcross, R, Bromley, RL, Irwin, B, etal, on behalf of the Liverpool/Manchester Neurodevelopment Group and the UK Epilepsy and Pregnancy Register. Child development following in utero exposure: levetiracetam vs sodium valproate. Neurology. 2011; 76(4): 383–389.Google Scholar
34.Bromley, RL, Mawer, G, Clayton-Smith, J, Baker, GA, on behalf of the Liverpool and Manchester Neurodevelopment Group. Autism spectrum disorders following in utero exposure to antiepileptic drugs. Neurology. 2008; 71(28): 1923–1924.Google Scholar
35.Bromley, RL, Mawer, GE, Briggs, M, etal, on Behalf of the Liverpool and Manchester Neurodevelopment Group.. The prevalence of neurodevelopmental disorders in children prenatally exposed to antiepileptic drugs. J Neurol Neurosurg Psychiatry. 2013; 84(6): 637–643.Google Scholar
36.Johnson, CP, Myers, SM. American Academy of Pediatrics Council on Children with Disabilities. Identification and evaluation of children with autistic spectrum disorders. Pediatrics. 2007; 120(5): 1183–1215.Google Scholar
37.Nadebaum, C, Anderson, V, Vajda, F, etal. The Australian brain and cognition and antiepileptic drugs study: IQ in school-aged children exposed to sodium valproate and polytherapy. J Int Neuropsychol Soc. 2011; 17(1): 133–142.Google Scholar
38.Nadebaum, C, Anderson, V, Vajda, F, etal. Language skills of school-aged children prenatally exposed to antiepileptic drugs. Neurology. 2011; 76(8): 719–726.Google Scholar
39.Cummings, C, Stewart, M, Stevenson, M, Morrow, J, Nelson, J. Neurodevelopment of children exposed in utero to lamotrigine, sodium valproate and carbamazepine. Arch Dis Child. 2011; 96(7): 643–647.Google Scholar
40.Kantola-Sorsa, E, Gaily, E, Isoaho, M, Korkman, M. Neuropsychological outcomes in children of mothers with epilepsy. J Int Neuropsychol Soc. 2007; 13(4): 642–652.Google Scholar
41.Christensen, J, Grønborg, TK, Sørensen, MJ, etal. Prenatal valproate exposure and risk of autism spectrum disorders and childhood autism. JAMA. 2013; 309(16): 1696–1703.Google Scholar
42.Veiby, G, Daltvei, AK, Schjølberg, S, etal. Exposure to antiepileptic drugs in utero and child development: a prospective population-based study. Epilepsia. 2013; 54(8): 1462–1472.CrossRefGoogle ScholarPubMed
43.Rosner, B. Fundamentals of Biostatistics. Belmont, CA: Duxbury-Brooks/Cole; 2006.Google Scholar
44.Veiby, G, Engelsen, BA, Gilhus, NE. Early child development and exposure to antiepileptic drugs prenatally and through breastfeeding: a prospective cohort study on children of women with epilepsy. JAMA Neurol. 2013; 70(11): 1367–1374.Google Scholar
45.Thomas, JM, Benham, AL, Gean, M, etal. Practice parameters for the psychiatric assessment of infant and toddlers (0-36 months). American Academy of Child and Adolescent Psychiatry. J Am Acad Child Adolesc Psychiatry. 1997; 36(10 Suppl): S21–S36.Google Scholar
46.Meisels, SJ, Provence, S. Screening and Assessment: Guidelines for Identifying Young Disabled and Developmentally Vulnerable Children and Their Families. Washington, DC: Zero to Three/National Center for Clinical Infants Program; 1989.Google Scholar
47.Gentile, S. SSRIs in pregnancy and lactation with emphasis on neurodevelopmental outcome. CNS Drugs. 2005; 19(7): 623–633.Google Scholar
48.Thapar, A, Fowler, T, Rice, F, etal. Maternal smoking during pregnancy and attention deficit hyperactivity disorder symptoms in offspring. Am J Psychiatry. 2003; 160(11): 1985–1989.Google Scholar
49.Larsson, HJ, Eaton, WW, Madsen, KK. Risk factors for autism: perinatal factors, parental psychiatric history, and socioeconomic status. Am J Epidemiol. 2005; 161(10): 916–925.Google Scholar
50.Hultman, CM, Sparén, P, Cnattingius, S. Perinatal risk factors for infantile autism. Epidemiology. 2002; 13(4): 417–423.Google Scholar
51.Easterbrook, PJ, Berlin, JA, Gopalan, R, Matthews, DR. Publication bias in clinical research. Lancet. 1991; 337(8746): 867–872.Google Scholar
52.Wright, TL, Hoffman, LH, Davies, . Lithium teratogenicity. Lancet. 1970; 24; 2(7678): 876.Google Scholar
53.Pennell, PB, Klein, AM, Browning, N, etal, for the NEAD Study Group. Differential effects of antiepileptic drugs on neonatal outcomes. Epilepsy Behav. 2012; 24(4): 449–456.CrossRefGoogle ScholarPubMed
54.Fox, AW, Diamond, ML, Spiering, EL. Migraine during pregnancy: options for therapy. CNS Drugs. 2005; 19(6): 465–481.Google Scholar
55. Flunarizine. http://db.cbg-meb.nl/veegactie/csp/Flunarizine-December2010.doc. Accessed: July 14, 2013.Google Scholar
56.Holmes, LB, Hernandez-Diaz, S. Newer anticonvulsants: lamotrigine, topiramate and gabapentin. Birth Defects Res A Clin Mol Teratol. 2012; 94(8): 599–606.CrossRefGoogle ScholarPubMed
57.National Institute for Health and Clinical Excellence. The epilepsies: The diagnosis and management of the epilepsies in adults and children in primary and secondary care. http://www.nice.org.uk/nicemedia/live/13635/57784/57784.pdf. Accessed: July 16, 2013.Google Scholar
58.Campbell, E, Kennedy, F, Irwin, B, etal. Malformation risks of antiepileptic drug monotherapies in pregnancy. J Neurol Neurosurg Psychiatry. 2013; Nov; 84(11): e2.Google Scholar
59.Gentile, S. Lithium in pregnancy: the need to treat, the duty to ensure safety. Exp Opin Drug Saf. 2012; 11(3): 425–437.Google Scholar
60.Vajda, FJ, Graham, J, Roten, A, etal. Teratogenicity of the newer antiepileptic drugs—the Australian experience. J Clin Neurosci. 2012; 19(1): 57–59.Google Scholar
61.Gentile, S. Antipsychotic therapy during early and late pregnancy: a systematic review. Schizophr Bull. 2010; 36(3): 518–544.Google Scholar
62.Kjaer, D, Christensen, J, Becha, BH, etal. Preschool behavioral problems in children prenatally exposed to antiepileptic drugs—a follow-up study. Epilepsy Behav. 2013; 29(2): 407–411.Google Scholar
63.Boden, R, Lundgren, M, Brandt, L, etal. Risks of adverse pregnancy and birth outcomes in women treated or not treated with mood stabilisers for bipolar disorder: population based cohort study. BMJ. 2012; 345: e7085.Google Scholar
64. Mayo Clinic.Epilepsy and pregnancy: what you need to know. http://www.mayoclinic.com/health/pregnancy/PR00123. Accessed: September 30, 2013.Google Scholar
65.Frederick, IO, Qiu, C, Enquobahrie, DA, etal. Lifetime prevalence and correlates of migraine among women in a Pacific Northwest pregnancy cohort study. Headache. In press. doi: 10.1111/head.12206.CrossRefGoogle Scholar
66.Wright, G, Patel, M. Focal migraine and pregnancy. BMJ. 1986; 293(6561): 1557–1558.Google Scholar
67.MacGregor, EA. Headache in pregnancy. Neurol Clin. 2012; 30(3): 835–866.Google Scholar